Aim: To review the clinical features, management, and outcomes of surgical treatment of eyelid squamous cell carcinoma (SCC). Methods: A retrospective review of all eyelid SCCs treated between 1992 and 2001. Results: 51 cases were identified in 50 patients. Patient ages ranged from 26 to 93 years, with a mean age of 65 years. 33 patients were male and 17 were female. The lesion was found on the lower lid in 31 cases, upper lid in five cases, lateral canthus in six cases, and medial canthus in nine cases. Perineural invasion was found in four patients, and orbital invasion in three patients. Recurrence occurred in one patient. Treatment was by complete excision with histological confirmation of clear margins. Exenteration was required in three patients. No patients developed lymph node or distant metastases. One patient, who declined treatment, died as a result of the tumour. Mean follow up was 31.1 months. Conclusions: Eyelid SCC is a relatively uncommon, but potentially fatal disease. However, if detected early and treated adequately, the prognosis is generally excellent. Treatment by complete excision with histological confirmation of tumour clearance is recommended. Perineural spread is an adverse prognostic sign, which may require postoperative radiotherapy. Orbital invasion is a rare complication but, if recognised early, can be treated effectively with exenteration. Because presentation varies and histological examination is required for accurate diagnosis, any suspicious lesion occurring on the eyelids should be excised or biopsied. All patients with eyelid SCC should be advised of the risk of recurrent or new tumours and encouraged to attend lifelong follow up. Prevention remains of prime importance in minimising the morbidity and mortality of these lesions. S quamous cell carcinoma (SCC) is an invasive epithelial malignancy showing keratinocytic differentiation. It is the second most common malignant neoplasm of the eyelids, 1 comprising 5-10% of all eyelid malignancies. The incidence for eyelid SCC has been reported to be between 0.09 and 2.42 cases per 100 000 population.2 Extrinsic risk factors include ultraviolet light/actinic damage and exposure to arsenic, hydrocarbons, radiation, or immunosuppressive drugs. 3Intrinsic risk factors include albinism, pre-existing chronic skin lesions and genetic skin disorders such as xeroderma pigmentosum and epidermodysplasia verruciformis.Because of the significant morbidity of these lesions and in order to better define the clinical features and treatment outcomes, and to make management recommendations, we conducted a review of all eyelid SCCs treated over a 9 year period. METHODSA retrospective medical record review was conducted of all eyelid squamous cell carcinomas seen in the practice of one of the authors (TJS) in the 9 years from 1992 to 2001. Cases were identified by searching the practice records of the author and hospital and pathology laboratory computerised databases. Included were all lesions originating on the eyelids or canthi with a pathologica...

No abstract

No abstract

Aqueous chlorhexidine was associated with a low rate of postinjection endophthalmitis and was well tolerated by patients.

Purpose To evaluate the toxicity of 1 mg of intraocular rituximab and to present a small case-series of patients treated with intravitreal rituximab. Methods Rituximab (1 mg/0.1 ml) was injected in the vitreous of one eye of three Dutch-belted rabbits. Two animals were injected with balanced salt solution as controls. At 1 month the rabbits were killed and the eyes examined by light microscopy. Three patients (five eyes) with intraocular lymphoma were also treated with a 1 mg injection of rituximab. Results The treated rabbit eyes and the control eyes showed no light microscopic evidence of ocular toxicity at 1 month following injection. The five human eyes of three patients have shown no evidence of intraocular toxicity with a median follow-up time of 3.6 months (range 2.0-6.4 months). One patient received a total of four injections in the right eye and three injections in the left eye. Conclusion Intravitreal rituximab at a dose of 1 mg does not appear to cause toxicity in rabbit eyes and in the five eyes of three patients.